Literature DB >> 3471179

Ofloxacin pharmacokinetics in renal failure.

J P Fillastre, A Leroy, G Humbert.   

Abstract

The pharmacokinetics of ofloxacin were investigated in 12 normal subjects and 21 uremic patients after the administration of a single oral 200-mg dose. An open three-compartment body model was used to calculate ofloxacin pharmacokinetic parameters. In healthy subjects, the peak plasma level averaged 2.24 +/- 0.90 micrograms/ml and was obtained at 0.83 +/- 0.31 h. The absorption rate constant was 4.22 +/- 1.64 h-1. The terminal half-life was 7.86 +/- 1.81 h. The apparent volume of distribution was 2.53 +/- 0.78 liters/kg. Total body and renal clearances were 241.4 +/- 53.8 and 196.5 +/- 42.9 ml/min per 1.73 m2, respectively. A total of 68.4 +/- 11.9% of the dose was recovered unchanged in 24-h urine. In uremic patients, the terminal half-life increased in relation to the degree of renal failure: from 8 h in normal subjects to 37 h in severely uremic patients. Renal insufficiency did not significantly modify the peak plasma level, the apparent volume of distribution, the fractional clearance, or the nonrenal clearance of ofloxacin. However, the time to peak level was delayed in patients with creatinine clearance of less than 30 ml/min. Linear relationships were found between ofloxacin pharmacokinetic parameters and glomerular filtration rate data. Ofloxacin is only very slightly removed by hemodialysis. Dosage adjustments of ofloxacin in uremic patients are proposed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3471179      PMCID: PMC174682          DOI: 10.1128/AAC.31.2.156

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

Review 1.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

2.  Pharmacokinetics of norfloxacin in renal failure.

Authors:  J P Fillastre; T Hannedouche; A Leroy; G Humbert
Journal:  J Antimicrob Chemother       Date:  1984-10       Impact factor: 5.790

3.  In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors:  K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

4.  Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage.

Authors:  M Eandi; I Viano; F Di Nola; L Leone; E Genazzani
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267

5.  The pharmacokinetics and tissue penetration of ofloxacin.

Authors:  M R Lockley; R Wise; J Dent
Journal:  J Antimicrob Chemother       Date:  1984-12       Impact factor: 5.790

  5 in total
  19 in total

1.  Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients.

Authors:  D Kampf; K Borner; A Pustelnik
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Pharmacokinetics of a single dose of ofloxacin in healthy elderly subjects using noncompartmental and compartmental models.

Authors:  C M Rademaker; R W Jones; L J Notarianni; A van Dijk; J H Glerum; J Verhoef
Journal:  Pharm Weekbl Sci       Date:  1989-12-15

3.  The computation of biomarkers in pharmacokinetics with the aid of singular perturbation methods.

Authors:  Jie Ma; James P Keener
Journal:  J Math Biol       Date:  2018-07-28       Impact factor: 2.259

4.  Temafloxacin pharmacokinetics in subjects with normal and impaired renal function.

Authors:  G R Granneman; R Braeckman; J Kraut; S Shupien; J C Craft
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

5.  Effect of renal impairment on distribution of ofloxacin.

Authors:  A Sanchez Navarro; J Martinez Lanao; M M Sanchez Recio; A Domínguez-Gil Hurlé; J M Tabernero Romo; J C Gomez Sanchez; M M Terreiro Delgado
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

6.  Pharmacokinetics of ofloxacin after single and multiple intravenous infusions in healthy subjects.

Authors:  R Farinotti; J H Trouvin; V Bocquet; N Vermerie; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

7.  Effective monitoring of concentrations of ofloxacin in saliva of patients with chronic respiratory tract infections.

Authors:  F Koizumi; A Ohnishi; H Takemura; S Okubo; T Kagami; T Tanaka
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

Review 8.  Ofloxacin clinical pharmacokinetics.

Authors:  K C Lamp; E M Bailey; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

9.  Ofloxacin pharmacokinetics in mechanically ventilated patients.

Authors:  C Martin; D Lambert; B Bruguerolle; P Saux; J Freney; J Fleurette; H Meugnier; F Gouin
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

Review 10.  Ofloxacin pharmacokinetics in chronic renal failure and dialysis.

Authors:  N Lameire; B Rosenkranz; V Malerczyk; K H Lehr; N Veys; S Ringoir
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.